Katrin Preller, Ph.D.

Katrin Preller is a Research Group Lead at the University of Zurich and Principal Clinical Biomarker Lead at Boehringer Ingelheim. She received her Ph.D. in neuroscience from the University of Zurich. Her research focuses on the use of psilocybin for treating alcohol use disorder. She has published numerous papers on the topic and has presented her findings at international conferences.